Last reviewed · How we verify

NCT04399694

Identification and Characterization of Novel Non-Coding Variants That Contribute to Genetic Disorders

Completed Last updated 15 January 2026
What this trial tests

trial in Genetic Disease in 56 participants. Completed in 11 April 2024.

Timeline
3 March 2020
Primary endpoint
11 April 2024
11 April 2024

Quick facts

Lead sponsorDuke University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment56
Start date3 March 2020
Primary completion11 April 2024
Estimated completion11 April 2024
Sites1 location across United States

Conditions studied

Sponsor

Duke University

Who can join

Eligibility, any sex, with Genetic Disease or Inborn Errors of Metabolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to identify and characterize novel non-coding and splicing variants that may contribute to genetic disorders. We will particularly focus on patients with a diagnosed genetic disorder that has inconclusive genetic findings.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Genetic Disease

Currently open trials in the same condition.

Other Duke University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04399694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing